<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p115" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_115{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#t2_115{left:285px;bottom:827px;letter-spacing:-0.27px;}
#t3_115{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t4_115{left:341px;bottom:30px;}
#t5_115{left:348px;bottom:25px;letter-spacing:0.11px;}
#t6_115{left:377px;bottom:30px;}
#t7_115{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t8_115{left:540px;bottom:30px;}
#t9_115{left:546px;bottom:25px;letter-spacing:0.07px;}
#ta_115{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#tb_115{left:44px;bottom:63px;letter-spacing:0.1px;}
#tc_115{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_115{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_115{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_115{left:1111px;bottom:47px;letter-spacing:0.18px;}
#tg_115{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_115{left:445px;bottom:783px;letter-spacing:0.44px;word-spacing:-0.26px;}
#ti_115{left:548px;bottom:765px;letter-spacing:-0.13px;}
#tj_115{left:34px;bottom:757px;letter-spacing:0.08px;}
#tk_115{left:51px;bottom:752px;letter-spacing:0.1px;}
#tl_115{left:51px;bottom:738px;letter-spacing:0.1px;}
#tm_115{left:51px;bottom:724px;letter-spacing:0.09px;word-spacing:0.01px;}
#tn_115{left:34px;bottom:714px;letter-spacing:0.08px;}
#to_115{left:51px;bottom:710px;letter-spacing:0.09px;word-spacing:0.01px;}
#tp_115{left:51px;bottom:696px;letter-spacing:0.11px;}
#tq_115{left:34px;bottom:686px;letter-spacing:0.08px;}
#tr_115{left:51px;bottom:681px;letter-spacing:0.1px;word-spacing:-0.05px;}
#ts_115{left:51px;bottom:667px;letter-spacing:0.1px;}
#tt_115{left:51px;bottom:653px;letter-spacing:0.11px;}
#tu_115{left:34px;bottom:644px;letter-spacing:0.08px;}
#tv_115{left:51px;bottom:639px;letter-spacing:0.08px;word-spacing:0.01px;}
#tw_115{left:51px;bottom:625px;letter-spacing:0.1px;}
#tx_115{left:51px;bottom:611px;letter-spacing:0.09px;word-spacing:0.02px;}
#ty_115{left:34px;bottom:601px;letter-spacing:0.08px;}
#tz_115{left:51px;bottom:597px;letter-spacing:0.08px;}
#t10_115{left:51px;bottom:582px;letter-spacing:0.1px;}
#t11_115{left:51px;bottom:568px;letter-spacing:0.1px;}
#t12_115{left:34px;bottom:559px;letter-spacing:0.08px;}
#t13_115{left:51px;bottom:554px;letter-spacing:0.08px;word-spacing:0.03px;}
#t14_115{left:51px;bottom:540px;letter-spacing:0.02px;word-spacing:0.09px;}
#t15_115{left:34px;bottom:531px;letter-spacing:0.08px;}
#t16_115{left:51px;bottom:526px;letter-spacing:0.09px;word-spacing:0.01px;}
#t17_115{left:51px;bottom:512px;letter-spacing:0.1px;}
#t18_115{left:51px;bottom:498px;letter-spacing:0.09px;word-spacing:0.02px;}
#t19_115{left:34px;bottom:488px;letter-spacing:0.08px;}
#t1a_115{left:51px;bottom:484px;letter-spacing:0.08px;word-spacing:0.02px;}
#t1b_115{left:51px;bottom:469px;letter-spacing:0.1px;}
#t1c_115{left:51px;bottom:455px;letter-spacing:0.09px;word-spacing:0.01px;}
#t1d_115{left:34px;bottom:446px;letter-spacing:0.08px;}
#t1e_115{left:51px;bottom:441px;letter-spacing:0.08px;}
#t1f_115{left:51px;bottom:427px;letter-spacing:0.1px;}
#t1g_115{left:51px;bottom:413px;letter-spacing:0.11px;}
#t1h_115{left:34px;bottom:403px;letter-spacing:0.08px;}
#t1i_115{left:51px;bottom:399px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t1j_115{left:51px;bottom:385px;letter-spacing:0.1px;}
#t1k_115{left:51px;bottom:371px;letter-spacing:0.09px;word-spacing:0.01px;}
#t1l_115{left:34px;bottom:361px;letter-spacing:0.08px;}
#t1m_115{left:51px;bottom:356px;letter-spacing:0.08px;word-spacing:-0.03px;}
#t1n_115{left:51px;bottom:342px;letter-spacing:0.1px;}
#t1o_115{left:51px;bottom:328px;letter-spacing:0.09px;}
#t1p_115{left:51px;bottom:314px;letter-spacing:0.11px;}
#t1q_115{left:34px;bottom:304px;letter-spacing:0.08px;}
#t1r_115{left:51px;bottom:300px;letter-spacing:0.1px;word-spacing:-0.04px;}
#t1s_115{left:51px;bottom:286px;letter-spacing:0.1px;}
#t1t_115{left:51px;bottom:272px;letter-spacing:0.1px;}
#t1u_115{left:34px;bottom:262px;letter-spacing:0.08px;}
#t1v_115{left:51px;bottom:258px;letter-spacing:0.1px;}
#t1w_115{left:51px;bottom:243px;letter-spacing:0.09px;word-spacing:0.01px;}
#t1x_115{left:51px;bottom:229px;letter-spacing:0.1px;}
#t1y_115{left:51px;bottom:215px;letter-spacing:0.11px;}
#t1z_115{left:34px;bottom:206px;letter-spacing:0.08px;}
#t20_115{left:51px;bottom:201px;letter-spacing:0.08px;word-spacing:-0.02px;}
#t21_115{left:51px;bottom:187px;letter-spacing:0.1px;}
#t22_115{left:51px;bottom:173px;letter-spacing:0.1px;}
#t23_115{left:34px;bottom:163px;letter-spacing:0.08px;}
#t24_115{left:51px;bottom:159px;letter-spacing:0.1px;}
#t25_115{left:51px;bottom:144px;letter-spacing:0.08px;}
#t26_115{left:34px;bottom:135px;letter-spacing:0.08px;}
#t27_115{left:51px;bottom:130px;letter-spacing:0.09px;word-spacing:0.01px;}
#t28_115{left:51px;bottom:116px;letter-spacing:0.1px;word-spacing:-0.17px;}
#t29_115{left:617px;bottom:758px;letter-spacing:0.08px;}
#t2a_115{left:634px;bottom:754px;letter-spacing:0.06px;word-spacing:0.04px;}
#t2b_115{left:634px;bottom:740px;letter-spacing:0.09px;word-spacing:-0.01px;}
#t2c_115{left:634px;bottom:725px;letter-spacing:0.11px;word-spacing:-0.22px;}
#t2d_115{left:617px;bottom:716px;letter-spacing:0.08px;}
#t2e_115{left:634px;bottom:711px;letter-spacing:0.08px;word-spacing:0.02px;}
#t2f_115{left:634px;bottom:697px;letter-spacing:0.09px;word-spacing:0.01px;}
#t2g_115{left:634px;bottom:683px;letter-spacing:0.11px;}
#t2h_115{left:617px;bottom:674px;letter-spacing:0.08px;}
#t2i_115{left:634px;bottom:669px;letter-spacing:0.1px;}
#t2j_115{left:634px;bottom:655px;letter-spacing:0.1px;}
#t2k_115{left:634px;bottom:641px;letter-spacing:0.11px;}
#t2l_115{left:617px;bottom:631px;letter-spacing:0.08px;}
#t2m_115{left:634px;bottom:627px;letter-spacing:0.08px;}
#t2n_115{left:634px;bottom:612px;letter-spacing:0.09px;}
#t2o_115{left:634px;bottom:598px;letter-spacing:0.09px;word-spacing:0.01px;}
#t2p_115{left:634px;bottom:584px;letter-spacing:0.11px;}
#t2q_115{left:617px;bottom:575px;letter-spacing:0.12px;}
#t2r_115{left:630px;bottom:570px;letter-spacing:0.09px;}
#t2s_115{left:658px;bottom:570px;letter-spacing:0.09px;word-spacing:-0.03px;}
#t2t_115{left:625px;bottom:556px;letter-spacing:0.1px;}
#t2u_115{left:625px;bottom:542px;letter-spacing:0.09px;word-spacing:0.02px;}
#t2v_115{left:617px;bottom:532px;letter-spacing:0.08px;}
#t2w_115{left:634px;bottom:528px;letter-spacing:0.09px;word-spacing:-0.04px;}
#t2x_115{left:634px;bottom:514px;letter-spacing:0.1px;}
#t2y_115{left:634px;bottom:499px;letter-spacing:0.11px;}
#t2z_115{left:617px;bottom:490px;letter-spacing:0.08px;}
#t30_115{left:634px;bottom:485px;letter-spacing:0.08px;word-spacing:-0.03px;}
#t31_115{left:634px;bottom:471px;letter-spacing:0.1px;}
#t32_115{left:634px;bottom:457px;letter-spacing:0.1px;}
#t33_115{left:634px;bottom:443px;letter-spacing:0.11px;}
#t34_115{left:617px;bottom:433px;letter-spacing:0.08px;}
#t35_115{left:634px;bottom:429px;letter-spacing:0.09px;}
#t36_115{left:625px;bottom:415px;letter-spacing:0.1px;}
#t37_115{left:625px;bottom:400px;letter-spacing:0.11px;}
#t38_115{left:617px;bottom:391px;letter-spacing:0.08px;}
#t39_115{left:634px;bottom:386px;letter-spacing:0.08px;word-spacing:-0.02px;}
#t3a_115{left:625px;bottom:372px;letter-spacing:0.1px;}
#t3b_115{left:625px;bottom:358px;letter-spacing:0.1px;}
#t3c_115{left:617px;bottom:349px;letter-spacing:0.08px;}
#t3d_115{left:634px;bottom:344px;letter-spacing:0.04px;word-spacing:-0.03px;}
#t3e_115{left:829px;bottom:344px;letter-spacing:0.1px;}
#t3f_115{left:625px;bottom:330px;letter-spacing:0.09px;}
#t3g_115{left:625px;bottom:316px;letter-spacing:0.11px;word-spacing:-0.08px;}
#t3h_115{left:617px;bottom:306px;letter-spacing:0.08px;}
#t3i_115{left:634px;bottom:302px;letter-spacing:0.1px;}
#t3j_115{left:690px;bottom:302px;letter-spacing:0.06px;word-spacing:-0.02px;}
#t3k_115{left:634px;bottom:287px;letter-spacing:0.1px;}
#t3l_115{left:634px;bottom:273px;letter-spacing:0.07px;word-spacing:0.03px;}
#t3m_115{left:617px;bottom:259px;letter-spacing:0.08px;word-spacing:0.01px;}
#t3n_115{left:625px;bottom:245px;letter-spacing:0.1px;}
#t3o_115{left:625px;bottom:231px;letter-spacing:0.08px;word-spacing:0.02px;}
#t3p_115{left:617px;bottom:221px;letter-spacing:0.08px;}
#t3q_115{left:634px;bottom:217px;letter-spacing:0.1px;}
#t3r_115{left:625px;bottom:203px;letter-spacing:0.1px;}
#t3s_115{left:625px;bottom:189px;letter-spacing:0.11px;}
#t3t_115{left:617px;bottom:174px;letter-spacing:0.09px;}
#t3u_115{left:625px;bottom:160px;letter-spacing:0.1px;}
#t3v_115{left:625px;bottom:146px;letter-spacing:0.1px;}
#t3w_115{left:617px;bottom:132px;letter-spacing:0.1px;}
#t3x_115{left:723px;bottom:132px;letter-spacing:0.05px;word-spacing:-0.01px;}
#t3y_115{left:625px;bottom:118px;letter-spacing:0.1px;}
#t3z_115{left:625px;bottom:104px;letter-spacing:0.1px;}
#t40_115{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_115{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s1_115{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s2_115{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s3_115{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_115{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_115{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_115{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_115{font-size:12px;font-family:ArialMT_k0;color:#000;}
.s8_115{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts115" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg115Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg115" style="-webkit-user-select: none;"><object width="1210" height="935" data="115/115.svg" type="image/svg+xml" id="pdf115" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_115" class="t s0_115">NCCN Guidelines Version 4.2024 </span>
<span id="t2_115" class="t s0_115">Head and Neck Cancers </span>
<span id="t3_115" class="t s1_115">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t4_115" class="t s2_115">® </span>
<span id="t5_115" class="t s1_115">(NCCN </span>
<span id="t6_115" class="t s2_115">® </span>
<span id="t7_115" class="t s1_115">), All rights reserved. NCCN Guidelines </span>
<span id="t8_115" class="t s2_115">® </span>
<span id="t9_115" class="t s1_115">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="ta_115" class="t s3_115">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="tb_115" class="t s3_115">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="tc_115" class="t s4_115">NCCN Guidelines Index </span>
<span id="td_115" class="t s4_115">Table of Contents </span>
<span id="te_115" class="t s4_115">Discussion </span>
<span id="tf_115" class="t s5_115">SYST-A </span>
<span id="tg_115" class="t s5_115">4 OF 4 </span>
<span id="th_115" class="t s5_115">PRINCIPLES OF SYSTEMIC THERAPY </span>
<span id="ti_115" class="t s5_115">REFERENCES </span>
<span id="tj_115" class="t s6_115">32 </span>
<span id="tk_115" class="t s7_115">Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab </span>
<span id="tl_115" class="t s6_115">with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck </span>
<span id="tm_115" class="t s6_115">(KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394:1915-1928. </span>
<span id="tn_115" class="t s6_115">33 </span>
<span id="to_115" class="t s6_115">Ferris RL, Blumenschein G, Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of </span>
<span id="tp_115" class="t s6_115">the head and neck. N Engl J Med 2016;375:1856-1867. </span>
<span id="tq_115" class="t s6_115">34 </span>
<span id="tr_115" class="t s7_115">Chow LQ, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected </span>
<span id="ts_115" class="t s6_115">patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the </span>
<span id="tt_115" class="t s6_115">phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016;34:3838-3845. </span>
<span id="tu_115" class="t s6_115">35 </span>
<span id="tv_115" class="t s7_115">Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or </span>
<span id="tw_115" class="t s6_115">cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a </span>
<span id="tx_115" class="t s6_115">randomised, open-label, phase 3 study. Lancet 2019;393:156-167. </span>
<span id="ty_115" class="t s6_115">36 </span>
<span id="tz_115" class="t s7_115">Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of </span>
<span id="t10_115" class="t s6_115">recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, </span>
<span id="t11_115" class="t s6_115">multicentre, phase 1b trial. Lancet Oncol 2016;17:956-965. </span>
<span id="t12_115" class="t s6_115">37 </span>
<span id="t13_115" class="t s6_115">Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and </span>
<span id="t14_115" class="t s6_115">neck cancer. N Engl J Med 2008;359:1116-1127. </span>
<span id="t15_115" class="t s6_115">38 </span>
<span id="t16_115" class="t s7_115">Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo </span>
<span id="t17_115" class="t s6_115">compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern </span>
<span id="t18_115" class="t s6_115">Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-8654. </span>
<span id="t19_115" class="t s6_115">39 </span>
<span id="t1a_115" class="t s6_115">Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/carboplatin </span>
<span id="t1b_115" class="t s6_115">in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a </span>
<span id="t1c_115" class="t s6_115">Southwest Oncology Group Phase II study. Cancer Invest 2007;25:182-188. </span>
<span id="t1d_115" class="t s6_115">40 </span>
<span id="t1e_115" class="t s7_115">Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus </span>
<span id="t1f_115" class="t s6_115">cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern </span>
<span id="t1g_115" class="t s6_115">Cooperative Oncology Group. J Clin Oncol 2005;23:3562-3567. </span>
<span id="t1h_115" class="t s6_115">41 </span>
<span id="t1i_115" class="t s7_115">Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and </span>
<span id="t1j_115" class="t s6_115">carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head </span>
<span id="t1k_115" class="t s6_115">and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-1251. </span>
<span id="t1l_115" class="t s6_115">42 </span>
<span id="t1m_115" class="t s6_115">Guigay J, Fayette J, Dillies A-F, et al. Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment </span>
<span id="t1n_115" class="t s6_115">in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): </span>
<span id="t1o_115" class="t s6_115">Final results of phase II trial GORTEC 2008-03 [abstract]. J Clin Oncol 2012;30(suppl 15):Abstract </span>
<span id="t1p_115" class="t s6_115">5505. </span>
<span id="t1q_115" class="t s6_115">43 </span>
<span id="t1r_115" class="t s6_115">Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor </span>
<span id="t1s_115" class="t s6_115">receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the </span>
<span id="t1t_115" class="t s6_115">head and neck. J Clin Oncol 2005;23:5578-5587. </span>
<span id="t1u_115" class="t s6_115">44 </span>
<span id="t1v_115" class="t s7_115">Dzienis M, Cundom J, Fuentes CS, et al. Pembrolizumab + carboplatin + paclitaxel as first-line therapy </span>
<span id="t1w_115" class="t s6_115">in recurrent/metastatic head and neck squamous cell carcinoma: Phase 4 KEYNOTE-B10 study. </span>
<span id="t1x_115" class="t s6_115">presented at european society for medical oncology (ESMO) congress; September 9-13, 2022; Paris, </span>
<span id="t1y_115" class="t s6_115">France. </span>
<span id="t1z_115" class="t s6_115">45 </span>
<span id="t20_115" class="t s7_115">Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and </span>
<span id="t21_115" class="t s6_115">fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and </span>
<span id="t22_115" class="t s6_115">neck. J Clin Oncol 1992;10:257-263. </span>
<span id="t23_115" class="t s6_115">46 </span>
<span id="t24_115" class="t s6_115">Al-Sarraf M, Metch B, Kish J, et al. Platinum analogs in recurrent and advanced head and neck cancer: </span>
<span id="t25_115" class="t s6_115">a Southwest Oncology Group and Wayne State University Study. Cancer Treat Rep 1987;71:723-726. </span>
<span id="t26_115" class="t s6_115">47 </span>
<span id="t27_115" class="t s6_115">Grau JJ, Caballero M, Verger E, et al. Weekly paclitaxel for platin-resistant stage IV head and neck </span>
<span id="t28_115" class="t s6_115">cancer patients. Acta Otolaryngol 2009;129:1294-1299. </span>
<span id="t29_115" class="t s6_115">48 </span>
<span id="t2a_115" class="t s6_115">Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of </span>
<span id="t2b_115" class="t s6_115">patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials </span>
<span id="t2c_115" class="t s6_115">Group. Ann Oncol 1994;5:533-537. </span>
<span id="t2d_115" class="t s6_115">49 </span>
<span id="t2e_115" class="t s6_115">Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing </span>
<span id="t2f_115" class="t s6_115">docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer </span>
<span id="t2g_115" class="t s6_115">2004;40:2071-2076. </span>
<span id="t2h_115" class="t s6_115">50 </span>
<span id="t2i_115" class="t s6_115">Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous </span>
<span id="t2j_115" class="t s6_115">methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol </span>
<span id="t2k_115" class="t s6_115">2009;27:1864-1871. </span>
<span id="t2l_115" class="t s6_115">51 </span>
<span id="t2m_115" class="t s6_115">Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate </span>
<span id="t2n_115" class="t s6_115">the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic </span>
<span id="t2o_115" class="t s6_115">squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J </span>
<span id="t2p_115" class="t s6_115">Clin Oncol 2007;25:2171-2177. </span>
<span id="t2q_115" class="t s6_115">52 </span>
<span id="t2r_115" class="t s6_115">Fury </span><span id="t2s_115" class="t s7_115">MG, Sherman E, Lisa D, et al. A randomized phase II study of cetuximab every 2 weeks at </span>
<span id="t2t_115" class="t s6_115">either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell </span>
<span id="t2u_115" class="t s6_115">cancer. J Natl Compr Canc Netw 2012;10:1391-1398. </span>
<span id="t2v_115" class="t s6_115">53 </span>
<span id="t2w_115" class="t s7_115">Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment </span>
<span id="t2x_115" class="t s6_115">for patients with recurrent and metastatic squamous head and neck cancer after previous platinum- </span>
<span id="t2y_115" class="t s6_115">based treatment. Br J Cancer 2010;102:1687-1691. </span>
<span id="t2z_115" class="t s6_115">54 </span>
<span id="t30_115" class="t s6_115">Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in </span>
<span id="t31_115" class="t s6_115">patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing </span>
<span id="t32_115" class="t s6_115">on or after platinum-based therapy (LUX-Head &amp; Neck 1): an open-label, randomised phase 3 trial. </span>
<span id="t33_115" class="t s6_115">Lancet Oncol 2015;16:583-594. </span>
<span id="t34_115" class="t s6_115">55 </span>
<span id="t35_115" class="t s6_115">Chung CH, Li J, Steuer CE, et al. Phase II multi-institutional clinical trial result of concurrent </span>
<span id="t36_115" class="t s6_115">cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma. </span>
<span id="t37_115" class="t s6_115">Clin Cancer Res 2022;28:2329-2338. </span>
<span id="t38_115" class="t s6_115">56 </span>
<span id="t39_115" class="t s7_115">Sacco AG, Chen R, Worden FP, et al Pembrolizumab plus cetuximab in patients with recurrent or </span>
<span id="t3a_115" class="t s6_115">metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, </span>
<span id="t3b_115" class="t s6_115">multicentre, phase 2 trial. Lancet Oncol 2021;22:883-892. </span>
<span id="t3c_115" class="t s6_115">57 </span>
<span id="t3d_115" class="t s6_115">Bossi P, Miceli R, Locati LD, et al. A </span><span id="t3e_115" class="t s7_115">randomized, phase 2 study of cetuximab plus cisplatin with or </span>
<span id="t3f_115" class="t s6_115">without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell </span>
<span id="t3g_115" class="t s6_115">carcinoma of the head and neck Ann Oncol 2017;28:2820-2826 </span>
<span id="t3h_115" class="t s6_115">58 </span>
<span id="t3i_115" class="t s6_115">Marabelle </span><span id="t3j_115" class="t s7_115">A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high </span>
<span id="t3k_115" class="t s6_115">microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 </span>
<span id="t3l_115" class="t s6_115">study. J Clin Oncol 2020;38:1-10. </span>
<span id="t3m_115" class="t s6_115">59 Urba S, van Herpen CML, Sahoo TP, et al. Pemetrexed in combination with cisplatin versus </span>
<span id="t3n_115" class="t s6_115">cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a </span>
<span id="t3o_115" class="t s7_115">randomized, double-blind, placebo-controlled, phase 3 study. Cancer 2012;118:4694-4705. </span>
<span id="t3p_115" class="t s6_115">60 </span>
<span id="t3q_115" class="t s6_115">Malhotra B, Moon J, Kucuk O, et al. Phase II trial of biweekly gemcitabine and paclitaxel with </span>
<span id="t3r_115" class="t s6_115">recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group </span>
<span id="t3s_115" class="t s6_115">study S0329. Head Neck 2014;36:1712-1717. </span>
<span id="t3t_115" class="t s6_115">61 Haddad RI, Harrington K, Tahara M, et al. Nivolumab plus ipilimumab versus EXTREME regimen </span>
<span id="t3u_115" class="t s6_115">as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: Final </span>
<span id="t3v_115" class="t s6_115">results of CheckMate 651. J Clin Oncol 2023;41:2166-2180. </span>
<span id="t3w_115" class="t s6_115">62 Meric-Bernstam </span><span id="t3x_115" class="t s7_115">F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in </span>
<span id="t3y_115" class="t s6_115">patients with her2-expressing solid tumors: Primary results from the destiny-pantumor02 phase ii trial. </span>
<span id="t3z_115" class="t s6_115">J Clin Oncol 2024;42:47-58. </span>
<span id="t40_115" class="t s8_115">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
